Tau aggregates as immunotherapeutic targets

Diana L. Castillo-Carranza, Cristian A. Lasagna-Reeves, Rakez Kayed

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Pathological aggregation of the microtubuleassociated protein tau and accumulation of neurofibrillary tangles (NFT) and other inclusions containing hyperphosphorylated tau are defining histopathological features of Alzheimer disease (AD) and many other neurodegenerative diseases collectively known as tauopathies. The toxicity of tau aggregates has been demonstrated in vitro and in vivo; thus, their clearance by immunotherapy holds clinical promise. Published studies, which are limited in number, have exclusively focused on the clearance of hyperphosphorylated large tau aggregates, e.g., NFT. However, recent studies using human tissues and mouse models have questioned the toxicity and the presumed role of NFT in the progression of tauopathies and challenged the view of tangles as toxic species in the brain. Together, these novel studies have demonstrated that prefilamentous tau oligomers rather than NFT play a crucial role in these disorders. Here, we summarize recent advances in this new field, highlight the role of tau oligomers and their potential as a therapeutic target for the treatment of AD and other neurodegenerative tauopathies, and discuss the challenges that lie ahead.

Original languageEnglish (US)
Pages (from-to)426-438
Number of pages13
JournalFrontiers in Bioscience - Scholar
Volume5 S
Issue number2
StatePublished - Jan 1 2013


  • Alzheimer disease
  • Clearance
  • Immunotherapy
  • Review
  • Tau oligomers

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • General Immunology and Microbiology


Dive into the research topics of 'Tau aggregates as immunotherapeutic targets'. Together they form a unique fingerprint.

Cite this